Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels
Identifieur interne : 000681 ( Istex/Corpus ); précédent : 000680; suivant : 000682Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels
Auteurs : B. J. Snow ; I. Tooyama ; I. Mcgeer ; T. Yamada ; D. B. Calne ; H. Takahashi ; H. KimuraSource :
- Annals of Neurology [ 0364-5134 ] ; 1993-09.
Abstract
Postmortem counts of dopaminergic cell densities in the substantia nigra (5 subjects) and striatal levels of dopamine (DA) and its metabolites (6 subjects) were determined on 1 parkinsonian (PD), 3 progressive supranuclear palsy (PSP), 1 amyotrophic lateral sclerosis, and 1 Alzheimer's case who had been positron emission tomography scanned with 6‐[18F]fluorodopa during life. [18F]Fluorodopa uptake rate constants, which presumably depend on the number of functioning striatal DA terminals, were strictly proportional to cell densities (significant correlation with zero intercept) and also correlated significantly with striatal DA levels but with an intercept indicating greater losses of DA than of terminals in PSP and PD. Postmortem data on 6 PD, 1 PSP, and 9 neuronally normal controls substantiated the significant correlation between cell counts and DA levels, with the latter being the more depressed in pathological cases.
Url:
DOI: 10.1002/ana.410340304
Links to Exploration step
ISTEX:00AD1D7AABD51B4C53EF3596B92D91F83706C27ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels</title><author><name sortKey="Snow, B J" sort="Snow, B J" uniqKey="Snow B" first="B. J." last="Snow">B. J. Snow</name><affiliation><mods:affiliation>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation></affiliation></author><author><name sortKey="Tooyama, I" sort="Tooyama, I" uniqKey="Tooyama I" first="I." last="Tooyama">I. Tooyama</name><affiliation><mods:affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Institute of Molecular Neurobiology, Shiga University of Medical Science, Otsu, Seta, Japan</mods:affiliation></affiliation></author><author><name sortKey="Mcgeer, I" sort="Mcgeer, I" uniqKey="Mcgeer I" first="I." last="Mcgeer">I. Mcgeer</name><affiliation><mods:affiliation>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, 2255 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 1Z3</mods:affiliation></affiliation></author><author><name sortKey="Yamada, T" sort="Yamada, T" uniqKey="Yamada T" first="T." last="Yamada">T. Yamada</name><affiliation><mods:affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation></affiliation></author><author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D. B." last="Calne">D. B. Calne</name><affiliation><mods:affiliation>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation></affiliation></author><author><name sortKey="Takahashi, H" sort="Takahashi, H" uniqKey="Takahashi H" first="H." last="Takahashi">H. Takahashi</name><affiliation><mods:affiliation>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation></affiliation></author><author><name sortKey="Kimura, H" sort="Kimura, H" uniqKey="Kimura H" first="H." last="Kimura">H. Kimura</name><affiliation><mods:affiliation>Institute of Molecular Neurobiology, Shiga University of Medical Science, Otsu, Seta, Japan</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:00AD1D7AABD51B4C53EF3596B92D91F83706C27E</idno><date when="1993" year="1993">1993</date><idno type="doi">10.1002/ana.410340304</idno><idno type="url">https://api-v5.istex.fr/document/00AD1D7AABD51B4C53EF3596B92D91F83706C27E/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000681</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000681</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels</title><author><name sortKey="Snow, B J" sort="Snow, B J" uniqKey="Snow B" first="B. J." last="Snow">B. J. Snow</name><affiliation><mods:affiliation>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation></affiliation></author><author><name sortKey="Tooyama, I" sort="Tooyama, I" uniqKey="Tooyama I" first="I." last="Tooyama">I. Tooyama</name><affiliation><mods:affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Institute of Molecular Neurobiology, Shiga University of Medical Science, Otsu, Seta, Japan</mods:affiliation></affiliation></author><author><name sortKey="Mcgeer, I" sort="Mcgeer, I" uniqKey="Mcgeer I" first="I." last="Mcgeer">I. Mcgeer</name><affiliation><mods:affiliation>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, 2255 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 1Z3</mods:affiliation></affiliation></author><author><name sortKey="Yamada, T" sort="Yamada, T" uniqKey="Yamada T" first="T." last="Yamada">T. Yamada</name><affiliation><mods:affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation></affiliation></author><author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D. B." last="Calne">D. B. Calne</name><affiliation><mods:affiliation>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation></affiliation></author><author><name sortKey="Takahashi, H" sort="Takahashi, H" uniqKey="Takahashi H" first="H." last="Takahashi">H. Takahashi</name><affiliation><mods:affiliation>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation></affiliation></author><author><name sortKey="Kimura, H" sort="Kimura, H" uniqKey="Kimura H" first="H." last="Kimura">H. Kimura</name><affiliation><mods:affiliation>Institute of Molecular Neurobiology, Shiga University of Medical Science, Otsu, Seta, Japan</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1993-09">1993-09</date><biblScope unit="volume">34</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="324">324</biblScope><biblScope unit="page" to="330">330</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">00AD1D7AABD51B4C53EF3596B92D91F83706C27E</idno><idno type="DOI">10.1002/ana.410340304</idno><idno type="ArticleID">ANA410340304</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Postmortem counts of dopaminergic cell densities in the substantia nigra (5 subjects) and striatal levels of dopamine (DA) and its metabolites (6 subjects) were determined on 1 parkinsonian (PD), 3 progressive supranuclear palsy (PSP), 1 amyotrophic lateral sclerosis, and 1 Alzheimer's case who had been positron emission tomography scanned with 6‐[18F]fluorodopa during life. [18F]Fluorodopa uptake rate constants, which presumably depend on the number of functioning striatal DA terminals, were strictly proportional to cell densities (significant correlation with zero intercept) and also correlated significantly with striatal DA levels but with an intercept indicating greater losses of DA than of terminals in PSP and PD. Postmortem data on 6 PD, 1 PSP, and 9 neuronally normal controls substantiated the significant correlation between cell counts and DA levels, with the latter being the more depressed in pathological cases.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>B. J. Snow MD</name><affiliations><json:string>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, British Columbia, Canada</json:string></affiliations></json:item><json:item><name>I. Tooyama MD, PhD.</name><affiliations><json:string>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada</json:string><json:string>Institute of Molecular Neurobiology, Shiga University of Medical Science, Otsu, Seta, Japan</json:string></affiliations></json:item><json:item><name>Dr. McGeer PhD.</name><affiliations><json:string>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, British Columbia, Canada</json:string><json:string>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada</json:string><json:string>Kinsmen Laboratory of Neurological Research, University of British Columbia, 2255 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 1Z3</json:string></affiliations></json:item><json:item><name>T. Yamada MD, PhD.</name><affiliations><json:string>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada</json:string></affiliations></json:item><json:item><name>D. B. Calne MD</name><affiliations><json:string>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, British Columbia, Canada</json:string></affiliations></json:item><json:item><name>H. Takahashi MD</name><affiliations><json:string>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, British Columbia, Canada</json:string></affiliations></json:item><json:item><name>H. Kimura MD, PhD.</name><affiliations><json:string>Institute of Molecular Neurobiology, Shiga University of Medical Science, Otsu, Seta, Japan</json:string></affiliations></json:item></author><articleId><json:string>ANA410340304</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Postmortem counts of dopaminergic cell densities in the substantia nigra (5 subjects) and striatal levels of dopamine (DA) and its metabolites (6 subjects) were determined on 1 parkinsonian (PD), 3 progressive supranuclear palsy (PSP), 1 amyotrophic lateral sclerosis, and 1 Alzheimer's case who had been positron emission tomography scanned with 6‐[18F]fluorodopa during life. [18F]Fluorodopa uptake rate constants, which presumably depend on the number of functioning striatal DA terminals, were strictly proportional to cell densities (significant correlation with zero intercept) and also correlated significantly with striatal DA levels but with an intercept indicating greater losses of DA than of terminals in PSP and PD. Postmortem data on 6 PD, 1 PSP, and 9 neuronally normal controls substantiated the significant correlation between cell counts and DA levels, with the latter being the more depressed in pathological cases.</abstract><qualityIndicators><score>5.423</score><pdfVersion>1.3</pdfVersion><pdfPageSize>576 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>934</abstractCharCount><pdfWordCount>3803</pdfWordCount><pdfCharCount>23846</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>135</abstractWordCount></qualityIndicators><title>Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels</title><genre><json:string>article</json:string></genre><host><title>Annals of Neurology</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1531-8249</json:string></doi><issn><json:string>0364-5134</json:string></issn><eissn><json:string>1531-8249</json:string></eissn><publisherId><json:string>ANA</json:string></publisherId><volume>34</volume><issue>3</issue><pages><first>324</first><last>330</last><total>7</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Original Article</value></json:item></subject></host><categories><wos><json:string>science</json:string><json:string>neurosciences</json:string><json:string>clinical neurology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string><json:string>neurologie</json:string></inist></categories><publicationDate>1993</publicationDate><copyrightDate>1993</copyrightDate><doi><json:string>10.1002/ana.410340304</json:string></doi><id>00AD1D7AABD51B4C53EF3596B92D91F83706C27E</id><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api-v5.istex.fr/document/00AD1D7AABD51B4C53EF3596B92D91F83706C27E/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api-v5.istex.fr/document/00AD1D7AABD51B4C53EF3596B92D91F83706C27E/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api-v5.istex.fr/document/00AD1D7AABD51B4C53EF3596B92D91F83706C27E/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Copyright © 1993 American Neurological Association</p></availability><date>1993</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels</title><author xml:id="author-1"><persName><forename type="first">B. J.</forename><surname>Snow</surname></persName><roleName type="degree">MD</roleName><affiliation>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, British Columbia, Canada</affiliation></author><author xml:id="author-2"><persName><forename type="first">I.</forename><surname>Tooyama</surname></persName><roleName type="degree">MD, PhD.</roleName><affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada</affiliation><affiliation>Institute of Molecular Neurobiology, Shiga University of Medical Science, Otsu, Seta, Japan</affiliation></author><author xml:id="author-3"><persName><surname>McGeer</surname></persName><roleName type="degree">Dr.</roleName><affiliation>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, British Columbia, Canada</affiliation><affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada</affiliation><affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, 2255 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 1Z3</affiliation></author><author xml:id="author-4"><persName><forename type="first">T.</forename><surname>Yamada</surname></persName><roleName type="degree">MD, PhD.</roleName><affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada</affiliation></author><author xml:id="author-5"><persName><forename type="first">D. B.</forename><surname>Calne</surname></persName><roleName type="degree">MD</roleName><affiliation>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, British Columbia, Canada</affiliation></author><author xml:id="author-6"><persName><forename type="first">H.</forename><surname>Takahashi</surname></persName><roleName type="degree">MD</roleName><affiliation>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, British Columbia, Canada</affiliation></author><author xml:id="author-7"><persName><forename type="first">H.</forename><surname>Kimura</surname></persName><roleName type="degree">MD, PhD.</roleName><affiliation>Institute of Molecular Neurobiology, Shiga University of Medical Science, Otsu, Seta, Japan</affiliation></author></analytic><monogr><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="pISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><idno type="DOI">10.1002/(ISSN)1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1993-09"></date><biblScope unit="volume">34</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="324">324</biblScope><biblScope unit="page" to="330">330</biblScope></imprint></monogr><idno type="istex">00AD1D7AABD51B4C53EF3596B92D91F83706C27E</idno><idno type="DOI">10.1002/ana.410340304</idno><idno type="ArticleID">ANA410340304</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1993</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Postmortem counts of dopaminergic cell densities in the substantia nigra (5 subjects) and striatal levels of dopamine (DA) and its metabolites (6 subjects) were determined on 1 parkinsonian (PD), 3 progressive supranuclear palsy (PSP), 1 amyotrophic lateral sclerosis, and 1 Alzheimer's case who had been positron emission tomography scanned with 6‐[18F]fluorodopa during life. [18F]Fluorodopa uptake rate constants, which presumably depend on the number of functioning striatal DA terminals, were strictly proportional to cell densities (significant correlation with zero intercept) and also correlated significantly with striatal DA levels but with an intercept indicating greater losses of DA than of terminals in PSP and PD. Postmortem data on 6 PD, 1 PSP, and 9 neuronally normal controls substantiated the significant correlation between cell counts and DA levels, with the latter being the more depressed in pathological cases.</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Original Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1993-01-28">Received</change><change when="1993-05-06">Registration</change><change when="1993-09">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api-v5.istex.fr/document/00AD1D7AABD51B4C53EF3596B92D91F83706C27E/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8249</doi><issn type="print">0364-5134</issn><issn type="electronic">1531-8249</issn><idGroup><id type="product" value="ANA"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="ANNALS OF NEUROLOGY">Annals of Neurology</title><title type="subtitle">Official Journal of the American Neurological Association and the Child Neurology Society</title><title type="short">Ann Neurol.</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi origin="wiley" registered="yes">10.1002/ana.v34:3</doi><numberingGroup><numbering type="journalVolume" number="34">34</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="1993-09">September 1993</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="4" status="forIssue"><doi origin="wiley" registered="yes">10.1002/ana.410340304</doi><idGroup><id type="unit" value="ANA410340304"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Original Article</title><title type="tocHeading1">Original Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 1993 American Neurological Association</copyright><eventGroup><event type="manuscriptReceived" date="1993-01-28"></event><event type="manuscriptRevised" date="1993-05-04"></event><event type="manuscriptAccepted" date="1993-05-06"></event><event type="firstOnline" date="2004-10-08"></event><event type="publishedOnlineFinalForm" date="2004-10-08"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.1 mode:FullText source:HeaderRef result:HeaderRef" date="2010-02-23"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-03"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst">324</numbering><numbering type="pageLast">330</numbering></numberingGroup><correspondenceTo>Kinsmen Laboratory of Neurological Research, University of British Columbia, 2255 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 1Z3</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ANA.ANA410340304.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="27"></count></countGroup><titleGroup><title type="main" xml:lang="en">Human positron emission tomographic [<sup>18</sup>F]Fluorodopa studies correlate with dopamine cell counts and levels</title><title type="short" xml:lang="en">Fluorodopa PET and DA Indices</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>B. J.</givenNames><familyName>Snow</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2 #af3"><personName><givenNames>I.</givenNames><familyName>Tooyama</familyName><degrees>MD, PhD.</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><honorifics>Dr.</honorifics><givenNames>E. G.</givenNames><familyName>McGeer</familyName><degrees>PhD.</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af2"><personName><givenNames>T.</givenNames><familyName>Yamada</familyName><degrees>MD, PhD.</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>D. B.</givenNames><familyName>Calne</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>H.</givenNames><familyName>Takahashi</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af3"><personName><givenNames>H.</givenNames><familyName>Kimura</familyName><degrees>MD, PhD.</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="CA" type="organization"><unparsedAffiliation>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, British Columbia, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="CA" type="organization"><unparsedAffiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="JP" type="organization"><unparsedAffiliation>Institute of Molecular Neurobiology, Shiga University of Medical Science, Otsu, Seta, Japan</unparsedAffiliation></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Postmortem counts of dopaminergic cell densities in the substantia nigra (5 subjects) and striatal levels of dopamine (DA) and its metabolites (6 subjects) were determined on 1 parkinsonian (PD), 3 progressive supranuclear palsy (PSP), 1 amyotrophic lateral sclerosis, and 1 Alzheimer's case who had been positron emission tomography scanned with 6‐[<sup>18</sup>F]fluorodopa during life. [<sup>18</sup>F]Fluorodopa uptake rate constants, which presumably depend on the number of functioning striatal DA terminals, were strictly proportional to cell densities (significant correlation with zero intercept) and also correlated significantly with striatal DA levels but with an intercept indicating greater losses of DA than of terminals in PSP and PD. Postmortem data on 6 PD, 1 PSP, and 9 neuronally normal controls substantiated the significant correlation between cell counts and DA levels, with the latter being the more depressed in pathological cases.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Fluorodopa PET and DA Indices</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels</title></titleInfo><name type="personal"><namePart type="given">B. J.</namePart><namePart type="family">Snow</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, British Columbia, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I.</namePart><namePart type="family">Tooyama</namePart><namePart type="termsOfAddress">MD, PhD.</namePart><affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada</affiliation><affiliation>Institute of Molecular Neurobiology, Shiga University of Medical Science, Otsu, Seta, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="termsOfAddress">Dr.</namePart><namePart type="family">McGeer</namePart><namePart type="termsOfAddress">PhD.</namePart><affiliation>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, British Columbia, Canada</affiliation><affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada</affiliation><affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, 2255 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 1Z3</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Yamada</namePart><namePart type="termsOfAddress">MD, PhD.</namePart><affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D. B.</namePart><namePart type="family">Calne</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, British Columbia, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Takahashi</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, British Columbia, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Kimura</namePart><namePart type="termsOfAddress">MD, PhD.</namePart><affiliation>Institute of Molecular Neurobiology, Shiga University of Medical Science, Otsu, Seta, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">1993-09</dateIssued><dateCaptured encoding="w3cdtf">1993-01-28</dateCaptured><dateValid encoding="w3cdtf">1993-05-06</dateValid><copyrightDate encoding="w3cdtf">1993</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">3</extent><extent unit="references">27</extent></physicalDescription><abstract lang="en">Postmortem counts of dopaminergic cell densities in the substantia nigra (5 subjects) and striatal levels of dopamine (DA) and its metabolites (6 subjects) were determined on 1 parkinsonian (PD), 3 progressive supranuclear palsy (PSP), 1 amyotrophic lateral sclerosis, and 1 Alzheimer's case who had been positron emission tomography scanned with 6‐[18F]fluorodopa during life. [18F]Fluorodopa uptake rate constants, which presumably depend on the number of functioning striatal DA terminals, were strictly proportional to cell densities (significant correlation with zero intercept) and also correlated significantly with striatal DA levels but with an intercept indicating greater losses of DA than of terminals in PSP and PD. Postmortem data on 6 PD, 1 PSP, and 9 neuronally normal controls substantiated the significant correlation between cell counts and DA levels, with the latter being the more depressed in pathological cases.</abstract><relatedItem type="host"><titleInfo><title>Annals of Neurology</title><subTitle>Official Journal of the American Neurological Association and the Child Neurology Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Ann Neurol.</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>Original Article</topic></subject><identifier type="ISSN">0364-5134</identifier><identifier type="eISSN">1531-8249</identifier><identifier type="DOI">10.1002/(ISSN)1531-8249</identifier><identifier type="PublisherID">ANA</identifier><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>324</start><end>330</end><total>7</total></extent></part></relatedItem><identifier type="istex">00AD1D7AABD51B4C53EF3596B92D91F83706C27E</identifier><identifier type="DOI">10.1002/ana.410340304</identifier><identifier type="ArticleID">ANA410340304</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1993 American Neurological Association</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000681 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000681 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:00AD1D7AABD51B4C53EF3596B92D91F83706C27E
|texte= Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels
}}
| This area was generated with Dilib version V0.6.29. |  |